Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
-
Published:2019-12
Issue:12
Volume:30
Page:1992-2003
-
ISSN:0923-7534
-
Container-title:Annals of Oncology
-
language:en
-
Short-container-title:Annals of Oncology
Author:
Clarke N.W.ORCID, Ali A., Ingleby F.C., Hoyle A., Amos C.L., Attard G., Brawley C.D., Calvert J., Chowdhury S., Cook A., Cross W., Dearnaley D.P., Douis H., Gilbert D., Gillessen S., Jones R.J., Langley R.E., MacNair A., Malik Z., Mason M.D., Matheson D., Millman R., Parker C.C., Ritchie A.W.S., Rush H., Russell J.M., Brown J., Beesley S., Birtle A., Capaldi L., Gale J., Gibbs S., Lydon A., Nikapota A., Omlin A., O'Sullivan J.M., Parikh O., Protheroe A., Rudman S., Srihari N.N., Simms M., Tanguay J.S., Tolan S., Wagstaff J., Wallace J., Wylie J., Zarkar A., Sydes M.R., Parmar M.K.B., James N.D.
Funder
Cancer Research UK Medical Research Council Astellas, Clovis Oncology, Janssen, Novartis, Pfizer and Sanofi-Aventis
Subject
Oncology,Hematology
Reference22 articles.
1. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial;James;Lancet,2016 2. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer;Xie;J Clin Oncol,2017 3. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer;Sweeney;N Engl J Med,2015 4. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial;Fizazi;Lancet Oncol,2019 5. Apalutamide for metastatic, castration-sensitive prostate cancer;Chi;N Engl J Med,2019
Cited by
302 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|